238 related articles for article (PubMed ID: 17520581)
21. Pharmacological background of EGFR targeting.
Castillo L; Etienne-Grimaldi MC; Fischel JL; Formento P; Magné N; Milano G
Ann Oncol; 2004 Jul; 15(7):1007-12. PubMed ID: 15205192
[TBL] [Abstract][Full Text] [Related]
22. Pharmacology of epidermal growth factor inhibitors.
Toffoli G; De Mattia E; Cecchin E; Biason P; Masier S; Corona G
Int J Biol Markers; 2007; 22(1 Suppl 4):S24-39. PubMed ID: 17520578
[TBL] [Abstract][Full Text] [Related]
23. Targeting epidermal growth factor receptor in solid tumors: critical evaluation of the biological importance of therapeutic monoclonal antibodies.
Gialeli Ch; Kletsas D; Mavroudis D; Kalofonos HP; Tzanakakis GN; Karamanos NK
Curr Med Chem; 2009; 16(29):3797-804. PubMed ID: 19747140
[TBL] [Abstract][Full Text] [Related]
24. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
Harding J; Burtness B
Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
[TBL] [Abstract][Full Text] [Related]
25. [Effects of cetuximab combined erlotinib on proliferation of human hepatocellular carcinoma cell lines HepG2 and Bel-7402].
Wei W; Guo RP; Li JQ; Xu L; Shi M; Zhang YQ
Ai Zheng; 2008 Apr; 27(4):386-92. PubMed ID: 18423125
[TBL] [Abstract][Full Text] [Related]
26. Understanding resistance to EGFR inhibitors-impact on future treatment strategies.
Wheeler DL; Dunn EF; Harari PM
Nat Rev Clin Oncol; 2010 Sep; 7(9):493-507. PubMed ID: 20551942
[TBL] [Abstract][Full Text] [Related]
27. Monoclonal antibodies targeting the epidermal growth factor receptor.
Bianco R; Daniele G; Ciardiello F; Tortora G
Curr Drug Targets; 2005 May; 6(3):275-87. PubMed ID: 15857288
[TBL] [Abstract][Full Text] [Related]
28. Epithelial growth factor receptor interacting agents.
Baselga J; Albanell J
Hematol Oncol Clin North Am; 2002 Oct; 16(5):1041-63. PubMed ID: 12512382
[TBL] [Abstract][Full Text] [Related]
29. Epidermal growth factor receptor-directed therapy in esophageal cancer.
Pande AU; Iyer RV; Rani A; Maddipatla S; Yang GY; Nwogu CE; Black JD; Levea CM; Javle MM
Oncology; 2007; 73(5-6):281-9. PubMed ID: 18477853
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic integration of signal transduction targeting agents and conventional anti-cancer treatments.
Melisi D; Troiani T; Damiano V; Tortora G; Ciardiello F
Endocr Relat Cancer; 2004 Mar; 11(1):51-68. PubMed ID: 15027885
[TBL] [Abstract][Full Text] [Related]
31. Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors.
Morelli MP; Cascone T; Troiani T; De Vita F; Orditura M; Laus G; Eckhardt SG; Pepe S; Tortora G; Ciardiello F
Ann Oncol; 2005 May; 16 Suppl 4():iv61-68. PubMed ID: 15923432
[TBL] [Abstract][Full Text] [Related]
32. Extending outcomes: epidermal growth factor receptor-targeted monoclonal antibodies in non-small-cell lung cancer.
Joy AA; Butts CA
Clin Lung Cancer; 2009 Mar; 10 Suppl 1():S24-9. PubMed ID: 19362943
[TBL] [Abstract][Full Text] [Related]
33. Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): a phase I study.
Ramalingam S; Forster J; Naret C; Evans T; Sulecki M; Lu H; Teegarden P; Weber MR; Belani CP
J Thorac Oncol; 2008 Mar; 3(3):258-64. PubMed ID: 18317068
[TBL] [Abstract][Full Text] [Related]
34. Why the epidermal growth factor receptor? The rationale for cancer therapy.
Baselga J
Oncologist; 2002; 7 Suppl 4():2-8. PubMed ID: 12202782
[TBL] [Abstract][Full Text] [Related]
35. [Anti-EGFR therapy: towards a "à la carte" targeting of hepatocellular carcinoma].
Fartoux L; Desbois-Mouthon C; Poupon R; Rosmorduc O
Gastroenterol Clin Biol; 2006 Oct; 30(10):1133-5. PubMed ID: 17075466
[No Abstract] [Full Text] [Related]
36. Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment.
Normanno N; Bianco C; De Luca A; Maiello MR; Salomon DS
Endocr Relat Cancer; 2003 Mar; 10(1):1-21. PubMed ID: 12653668
[TBL] [Abstract][Full Text] [Related]
37. Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.
Vokes EE; Chu E
Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):15-25. PubMed ID: 16736979
[TBL] [Abstract][Full Text] [Related]
38. Advances in EGFR-directed therapy in head and neck cancer.
Numico G; Silvestris N; Grazioso Russi E
Front Biosci (Schol Ed); 2011 Jan; 3(2):454-66. PubMed ID: 21196389
[TBL] [Abstract][Full Text] [Related]
39. [EGFR/HER1 inhibition: an example of new targeted therapies in non-small cell lung cancer].
Reck M; Kranich AL; Steinbach AK; Gatzemeier U
Med Klin (Munich); 2005 Dec; 100(12):785-93. PubMed ID: 16453093
[TBL] [Abstract][Full Text] [Related]
40. [Non-small-cell lung cancer].
Akita H; Kinoshita I
Gan To Kagaku Ryoho; 2008 May; 35(5):720-4. PubMed ID: 18487906
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
